RxDoctor Payments Data

Ranbir Dhillon, MD

Neurology · Attleboro, MANPI 1124090691

Payments from drug & device makers

$182,241in general payments, 2019–2025

Across 1,807 payments — averaging $100.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$52K
  • Sanofi$37K
  • Bristol Myers Squibb$27K
  • E.r. Squibb & Sons, L.L.C.$21K
  • Teva Pharmaceuticals USA, Inc.$9K
  • EMD Serono, Inc.$5K
  • plus $32K from 54 others

What the payments were for

  • Consulting fees$53,29229%
  • Speaking & faculty fees$73,68440%
  • Travel & lodging$11,4016%
  • Food & beverage$43,55424%
  • Education$3110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen162$51,620
Sanofi107$37,004
Bristol Myers Squibb107$27,078
E.r. Squibb & Sons, L.L.C.29$21,346
Teva Pharmaceuticals USA, Inc.47$8,623
EMD Serono, Inc.62$4,640
Novartis121$3,932
Lundbeck LLC103$2,592
AbbVie(2 entities)124$2,404
SK Life Science, Inc.67$2,039
Livanova USA, Inc.15$1,706
Merz Pharmaceuticals, LLC49$1,219
Johnson & Johnson45$1,142
Neurocrine Biosciences, Inc.38$1,065
AstraZeneca(2 entities)38$1,049
Amneal Pharmaceuticals LLC54$1,018
UCB, Inc.40$996
Pfizer42$986
Genentech USA, Inc.41$950
Neurelis, Inc.36$904
Lilly USA, LLC44$869
Biohaven Pharmaceuticals, Inc.16$768
Amgen(2 entities)40$723
Eisai Inc.27$584
CSL Behring20$569
Mallinckrodt Hospital Products Inc.21$562
Biohaven Pharmaceutical Holding Company Ltd.15$519
Sunovion Pharmaceuticals Inc.46$508
MDD US Operations, LLC23$490
Kyowa Kirin, Inc.16$414
Acadia Pharmaceuticals Inc27$404
Vanda Pharmaceuticals Inc.14$345
Grifols USA, LLC19$307
Acorda Therapeutics, Inc12$231
Sumitomo Pharma America, Inc.12$218
Mallinckrodt Enterprises LLC10$213
Supernus Pharmaceuticals, Inc.18$210
Argenx US, Inc.7$167
Ipsen Biopharmaceuticals, Inc7$162
Otsuka America Pharmaceutical, Inc.6$124
Merz North America, Inc.7$121
Adamas Pharmaceuticals, Inc.6$113
ANI Pharmaceuticals, Inc.5$111
Upsher-smith Laboratories LLC4$101
Banner Life Sciences, LLC3$101
Inspire Medical Systems, Inc.5$90
Xeris Pharmaceuticals, Inc.5$87
Sanofi-aventis U.S. LLC4$83
Neuropace, Inc.3$78
Impel Pharmaceuticals Inc.4$72
GE HealthCare9$71
Medtronic(2 entities)3$65
Tanabe Pharma America, Inc.3$57
Catalyst Pharmaceuticals, Inc.1$54
Microtransponder, Inc.1$45
Bardy Diagnostics, Inc.2$45
Life Molecular Imaging Ltd3$41
Avion Pharmaceuticals2$37
TG Therapeutics, Inc.2$35
Jazz Pharmaceuticals Inc.2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$182,241 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$309,465
Medicare patients
644
Services billed
16,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab98$953,033
Teriflunomide61$188,609
AustedoDeutetrabenazine29$168,262
RebifInterferon Beta-1a/Albumin12$119,820
Avonex (4 Pack)Interferon Beta-1a13$103,290
IngrezzaValbenazine Tosylate11$90,130
FingolimodFingolimod Hcl26$89,597
CopaxoneGlatiramer Acetate13$74,599
Dimethyl Fumarate45$60,750
Glatiramer Acetate36$56,738
Nurtec OdtRimegepant Sulfate19$33,904
XcopriCenobamate26$32,677
Dalfampridine ErDalfampridine86$23,441
Lamotrigine ErLamotrigine28$19,864
Aimovig AutoinjectorErenumab-Aooe19$18,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$8,623$242,86142 claims
EMD Serono, Inc.Rebif$4,640$119,82012 claims
BiogenAvonex (4 Pack)$51,620$103,29013 claims
Neurocrine Biosciences, Inc.Ingrezza$1,065$90,13011 claims
PfizerNurtec Odt$986$33,90419 claims
SK Life Science, Inc.Xcopri$2,039$32,67726 claims
Upsher-smith Laboratories LLCTopiramate$101$1,312139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.

Other neurology in Attleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →